Wedge Capital Management L L P NC acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 291,684 shares of the specialty pharmaceutical company’s stock, valued at approximately $32,497,000. Wedge Capital Management L L P NC owned 0.46% of Jazz Pharmaceuticals as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital World Investors acquired a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $171,943,000. Swedbank AB acquired a new stake in Jazz Pharmaceuticals in the second quarter worth approximately $106,936,000. Rubric Capital Management LP bought a new position in Jazz Pharmaceuticals during the 2nd quarter valued at $65,812,000. Pacer Advisors Inc. raised its stake in shares of Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after buying an additional 527,187 shares in the last quarter. Finally, Baupost Group LLC MA boosted its stake in Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after buying an additional 440,552 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.
Insider Activity at Jazz Pharmaceuticals
In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.20% of the company’s stock.
Jazz Pharmaceuticals Price Performance
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. As a group, sell-side analysts expect that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Piper Sandler cut their price target on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Wells Fargo & Company lowered their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Finally, Royal Bank of Canada boosted their price objective on shares of Jazz Pharmaceuticals from $174.00 to $175.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.14.
Get Our Latest Stock Analysis on Jazz Pharmaceuticals
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Recommended Stories
- Five stocks we like better than Jazz Pharmaceuticals
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Investing in the High PE Growth Stocks
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- How to buy stock: A step-by-step guide for beginnersÂ
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.